Nov 5 (Reuters) - Puma Biotechnology Inc:
* PUMA BIOTECHNOLOGY LICENSING PARTNER CANBRIDGE PHARMACEUTICALS RECEIVES REGISTRATION APPROVAL IN HONG KONG FOR NERLYNX® (NERATINIB) FOR EXTENDED ADJUVANT TREATMENT OF EARLY STAGE HORMONE RECEPTOR POSITIVE HER2-POSITIVE BREAST CANCER
* PUMA BIOTECHNOLOGY - CANBRIDGE PHARMACEUTICALS INC., HAS RECEIVED REGISTRATION APPROVAL FROM DEPARTMENT OF HEALTH IN HONG KONG TO MARKET NERLYNX Source text for Eikon: Further company coverage: